|
1
|
Asia-Pacific Working Party on Prevention
of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma
in the Asia-Pacific region: Consensus statements. J Gastroenterol
Hepatol. 25:657–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Z, Zhang C, Lou C, Yan F, Mao Y, Hong X
and Zhang Y: Comparison of percutaneous cryosurgery and surgical
resection for the treatment of small hepatocellular carcinoma.
Oncol Lett. 6:239–245. 2013.PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kinoshita A, Koike K and Nishino H:
Clinical features and prognosis of elderly patients with
hepatocellular carcinoma not indicated for surgical resection.
Geriatr Gerontol Int. 17:189–201. 2017. View Article : Google Scholar
|
|
6
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
10
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
11
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rege TA and Hagood JS: Thy-1 as a
regulator of cell-cell and cell-matrix interactions in axon
regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
FASEB J. 20:1045–1054. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamashita T, Honda M, Nakamoto Y, Baba M,
Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al:
Discrete nature of EpCAM+ and CD90+ cancer
stem cells in human hepatocellular carcinoma. Hepatology.
57:1484–1497. 2013. View Article : Google Scholar
|
|
15
|
Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau
CK, Li ML, Tam KH, Lam CT, Poon RT and Fan ST: Identification of
local and circulating cancer stem cells in human liver cancer.
Hepatology. 47:919–928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sukowati CH, Anfuso B, Torre G,
Francalanci P, Crocè LS and Tiribelli C: The expression of
CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro
study. PLoS One. 8:e768302013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen WC, Hsu HP, Li CY, Yang YJ, Hung YH,
Cho CY, Wang CY, Weng TY and Lai MD: Cancer stem cell marker CD90
inhibits ovarian cancer formation via β3 integrin. Int J Oncol.
49:1881–1889. 2016.PubMed/NCBI
|
|
18
|
Wang F, Nazarali AJ and Ji S: Circular
RNAs as potential biomarkers for cancer diagnosis and therapy. Am J
Cancer Res. 6:1167–1176. 2016.PubMed/NCBI
|
|
19
|
Li J, Yang J, Zhou P, Le Y, Zhou C, Wang
S, Xu D, Lin HK and Gong Z: Circular RNAs in cancer: Novel insights
into origins, properties, functions and implications. Am J Cancer
Res. 5:472–480. 2015.PubMed/NCBI
|
|
20
|
Qu S, Yang X, Li X, Wang J, Gao Y, Shang
R, Sun W, Dou K and Li H: Circular RNA: A new star of noncoding
RNAs. Cancer Lett. 365:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kulcheski FR, Christoff AP and Margis R:
Circular RNAs are miRNA sponges and can be used as a new class of
biomarker. J Biotechnol. 238:42–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu L, Yao T, Chen Q, Mo X, Hu Y and Guo J:
Screening differential circular RNA expression profiles reveals
hsa_circ_0004018 is associated with hepatocellular carcinoma.
Oncotarget. 8:58405–58416. 2017.PubMed/NCBI
|
|
23
|
Yu L, Gong X, Sun L, Zhou Q, Lu B and Zhu
L: The Circular RNA Cdr1as Act as an Oncogene in Hepatocellular
carcinoma through targeting miR-7 expression. PLoS One.
11:e01583472016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmittgen TD: Real-time quantitative PCR.
Methods. 25:383–385. 2001. View Article : Google Scholar
|
|
25
|
Chen LL and Yang L: Regulation of circRNA
biogenesis. RNA Biol. 12:381–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hansen TB, Jensen TI, Clausen BH, Bramsen
JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function
as efficient microRNA sponges. Nature. 495:384–388. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li F, Zhang L, Li W, Deng J, Zheng J, An
M, Lu J and Zhou Y: Circular RNA ITCH has inhibitory effect on ESCC
by suppressing the Wnt/β-catenin pathway. Oncotarget. 6:6001–6013.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li P, Chen S, Chen H, Mo X, Li T, Shao Y,
Xiao B and Guo J: Using circular RNA as a novel type of biomarker
in the screening of gastric cancer. Clin Chim Acta. 444:132–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bachmayr-Heyda A, Reiner AT, Auer K,
Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW,
Zeillinger R and Pils D: Correlation of circular RNA abundance with
viability-exemplified with colorectal and ovarian cancer,
idiopathic lung fibrosis, and normal human tissues. Sci Rep.
5:80572015. View Article : Google Scholar
|
|
30
|
Huang G, Zhu H, Shi Y, Wu W, Cai H and
Chen X: cir-ITCH plays an inhibitory role in colorectal cancer by
regulating the Wnt/β-catenin pathway. PLoS One. 10:e01312252015.
View Article : Google Scholar
|
|
31
|
Lingala S, Cui YY, Chen X, Ruebner BH,
Qian XF, Zern MA and Wu J: Immunohistochemical staining of cancer
stem cell markers in hepatocellular carcinoma. Exp Mol Pathol.
89:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ
and Hu RM: Overexpression of Thy1/CD90 in human hepatocellular
carcinoma is associated with HBV infection and poor prognosis. Acta
Histochem. 113:833–838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu XH, Xu LB, Liu C, Zhang R and Wang J:
Clinicopathological characteristics of 20 cases of hepatocellular
carcinoma with bile duct tumor thrombi. Dig Dis Sci. 56:252–259.
2011. View Article : Google Scholar
|
|
34
|
Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu
WC, Lau J, Wan T, Wang X, Yan Z, et al: Gene expression profiling
of liver cancer stem cells by RNA-sequencing. PLoS One.
7:e371592012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang R, An LY, Miao QF, Li FM, Han Y, Wang
HX, Liu DP, Chen R and Tang SQ: Effective elimination of liver
cancer stem-like cells by CD90 antibody targeted thermosensitive
magnetoliposomes. Oncotarget. 7:35894–35916. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han D, Li J, Wang H, Su X, Hou J, Gu Y,
Qian C, Lin Y, Liu X, Huang M, et al: Circular RNA circMTO1 acts as
the sponge of miR-9 to suppress hepatocellular carcinoma
progression. Hepatology. 66:1151–1164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z,
Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA
and potential novel biomarker for hepatocellular carcinoma. Cancer
Biomark. 16:161–169. 2016. View Article : Google Scholar
|
|
38
|
Yao Z, Luo J, Hu K, Lin J, Huang H, Wang
Q, Zhang P, Xiong Z, He C, Huang Z, et al: ZKSCAN1 gene and its
related circular RNA (circZKSCAN1) both inhibit hepatocellular
carcinoma cell growth, migration, and invasion but through
different signaling pathways. Mol Oncol. 11:422–437. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fulda S: Modulation of mitochondrial
apoptosis by PI3K inhibitors. Mitochondrion. 13:195–198. 2013.
View Article : Google Scholar
|
|
40
|
Fulda S: Synthetic lethality by
co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling.
Mitochondrion. 19:85–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gedaly R, Angulo P, Hundley J, Daily MF,
Chen C and Evers BM: PKI-587 and sorafenib targeting PI3K/AKT/mTOR
and Ras/Raf/MAPK pathways synergistically inhibit HCC cell
viability. J Surg Res. 176:542–548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pan Y, Zhang Y, Chen L, Liu Y, Feng Y and
Yan J: The critical role of Rab31 in cell viability and apoptosis
in cancer progression. Mol Neurobiol. 53:4431–4437. 2016.
View Article : Google Scholar
|
|
43
|
Sui Y, Zheng X and Zhao D: Rab p31
promoted hepatocellular carcinoma (HCC) progression via inhibition
of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumor
Biol. 36:8661–8670. 2015. View Article : Google Scholar
|
|
44
|
Liang M, Liu J, Ji H, Chen M, Zhao Y, Li
S, Zhang X and Li J: A Aconitum coreanum polysaccharide fraction
induces apoptosis of hepatocellular carcinoma (HCC) cells via
pituitary tumor transforming gene 1 (PTTG1)-mediated suppression of
the P13K/Akt and activation of p38 MAPK signaling pathway and
displays antitumor activity in vivo. Tumour Biol. 36:7085–7091.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng J, Li C, Wu X, Liu M, Sun X, Yang Y,
Hao M, Sheng S, Sun Y, Zhang H, et al: Astrocyte elevated gene-1
(AEG-1) shRNA sensitizes Huaier polysaccharide (HP)-induced
anti-metastatic potency via inactivating downstream P13K/Akt
pathway as well as augmenting cell-mediated immune response. Tumour
Biol. 35:4219–4224. 2014. View Article : Google Scholar : PubMed/NCBI
|
